Yahoo Finance Insider Sale: CFO Andy Sassine Sells 50,000 Shares of Arcturus Therapeutics Holdings Inc (ARCT)
On June 12, 2024, Andy Sassine, the Chief Financial Officer of Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), executed a significant transaction by selling 50,000 shares of the company. The sale was documented in an SEC Filing. Following this transaction, the insider now owns 220,526 shares of the company.
Arcturus Therapeutics Holdings Inc is a biotechnology company focused on the discovery, development, and commercialization of RNA therapeutics for rare diseases and vaccines. The company's diverse pipeline includes candidates in preclinical and clinical stages targeting various medical conditions.
Over the past year, the insider transaction history for Arcturus Therapeutics Holdings Inc shows a trend with 0 insider buys and 12 insider sells. Specifically, Andy Sassine has sold a total of 50,000 shares and has not purchased any shares in the same timeframe.
On the valuation front, shares of Arcturus Therapeutics Holdings Inc were trading at $32.03 on the day of the insider's recent transaction. This pricing gives the company a market cap of $834.887 million. According to the GF Value, which is set at $46.78, the stock is currently significantly undervalued, with a price-to-GF-Value ratio of 0.68.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the companys past returns and growth, and future business performance estimates from Morningstar analysts.
This recent insider sell by the CFO may be of interest to current and potential investors, providing insights into insider confidence and potential future stock performance.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
